Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response.
- Resource Type
- Letter
- Authors
- Babushok, Daria V.; Nelson, Ernest J.; Morrissette, Jennifer J. D.; Joshi, Shivam; Palmer, Matthew B.; Frank, Dale; Cambor, Carolyn L.; Hexner, Elizabeth O.
- Source
- Leukemia & Lymphoma. Mar2019, Vol. 60 Issue 3, p852-855. 4p.
- Subject
- *MYELOFIBROSIS
*HEMATOLOGIC malignancies
*AMYLOIDOSIS
- Language
- ISSN
- 1042-8194
The article discusses the case study on a 52-year-old patient diagnosed with a JAK2 V617F mutation-positive primary myelofibrosis. Images are presented depicting the patient's disease course and extramedullary complications. Also noted are images of end-stage extramedullary complications of myelofibrosis in a patient with ruxolitinib therapy.